Optional Sirolimus

Phase 2Small molecule

Eli Lilly

Optional Sirolimus is one of 12 small molecule programs targeting Frontotemporal Dementia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Frontotemporal DementiaActive, not recruiting

Frontotemporal DementiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Frontotemporal Dementia

#DrugCompanyPhaseTrials

Celexa

AbbVie

Approved

1 2

Namenda

AbbVie

Approved

1 3

Gocovri

GGrupo Espanol de Tumores Neuroendocrinos

Approved

1 4

Rapamune

PPrism Pharmaceuticals

Rayos

Glucophage

Brintellix

1 8

Medrol

Pfizer

Phase 1

1 9

NS101

NNeuracle Science Co., LTD.

Phase 2

1 10

Optional Sirolimus

Eli Lilly

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

PreclinicalActive, not recruiting

Frontotemporal Dementia

NCT04408625

Clinical

Trials by Indication[1]

Frontotemporal Dementia1 trial

A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients With Fronto-Temporal Dementia With Progranulin Mutations (FTD-GRN)

Active, not recruiting· Eli Lilly logo

Eli Lilly·Preclinical·NCT04408625·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Optional Sirolimus. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Optional Sirolimus compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Optional Sirolimus. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eli Lilly

Optional Sirolimus

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Frontotemporal Dementia1 trial

References

Drug Info

Quick Facts

Related News